Day: November 5, 2024

London — Two new cases of the mpox variant clade 1b detected in the U.K. are the first locally transmitted cases in Europe and the first outside Africa, the World Health Organization said Tuesday.

The U.K. Health Security Agency (UKHSA) confirmed late Monday that the two new cases were household contacts of Britain’s first case identified last week, bringing the country’s total confirmed cases to three.

The WHO warned that European states should be prepared for “rapid action” to contain the latest mpox variant, which spreads through close physical contact including sexual relations and sharing closed spaces.

The two cases are also the first to be locally transmitted outside Africa since August 2024, when the WHO declared the outbreak of the new variant an international public health emergency — its highest level of alarm.

Those affected are under specialist care and the risk to the U.K. population “remains low,” UKHSA said.

The original case was detected after the person traveled to several African countries on holiday and returned to the U.K. on Oct. 21.

The patient developed flu-like symptoms more than 24 hours later and, on Oct. 24, started to develop a rash that worsened in the following days.

Mpox, a viral disease related to smallpox, has two types, clade 1 and clade 2. Symptoms include fever, a skin rash or pus-filled blisters, swollen lymph nodes and body aches.

The WHO first declared an international public health emergency in 2022 over the spread of clade 2. That outbreak mostly affected gay and bisexual men in Europe and the United States.

Vaccination and awareness drives in many countries helped stem the number of worldwide cases and the WHO lifted the emergency in May 2023 after reporting 140 deaths out of around 87,400 cases.

In 2024, a two-pronged epidemic of clade 1 and clade 1b, a new strain that affects children, has spread widely in the Democratic Republic of Congo.

The new strain has also been recorded in neighboring Burundi, Kenya, Rwanda and Uganda, with imported cases in Sweden, India, Thailand, Germany and the U.K.
…

Geneva — The World Health Organization on Tuesday listed 17 pathogens that cause widespread disease and death, including HIV, malaria and tuberculosis, for which it said new vaccines were “urgently needed.”

The U.N. health agency said that it with its list was providing the first global effort to systematically prioritize endemic pathogens based on criteria including disease burdens, antimicrobial resistance risk and the socioeconomic impact.

“We need to do this because we would like to shift the focus from developing vaccines away from commercial returns towards regional and global health needs,” Mateusz Hasso-Agopsowicz, a WHO vaccine specialist, told reporters in Geneva via video link from Poland.

The study reconfirms longstanding priorities for vaccine research and development, including HIV, malaria and tuberculosis — three diseases that collectively kill nearly 2.5 million people each year, WHO said.

But it also identifies lesser-known pathogens as top disease control priorities, highlighting the urgency to develop new vaccines for pathogens that are becoming increasingly resistant to antimicrobials.

Among them was Group A streptococcus, which causes severe infections and contributes to some 280,000 deaths from rheumatic heart disease each year, mainly in lower-income countries.

Ita also highlights the dangers of Klebsiella pneumoniae — a bacterium that is responsible for around 40% of neonatal deaths due to blood infection, or sepsis, in low-income countries.

These vaccines “would not only significantly reduce diseases that greatly impact communities today but also reduce the medical costs that families and health systems face,” WHO vaccine chief Kate O’Brien said in a statement.

Vaccines for the various pathogens listed are at different stages of development, WHO said, with some like ones for HIV, Group A streptococcus and hepatitis C virus still at the research stage. 

Others, like ones for dengue and tuberculosis, have been developed and are approaching regulatory approval or introduction.

Hasso-Agopsowicz explained that the 17 listed pathogens were wreaking the most havoc in lower-income countries, explaining why more progress has not been made previously on developing vaccines against them.

“What typically has happened in the past is that vaccine research and development has been influenced by profitability of new vaccines. What that means is that diseases that severely affect low-income regions unfortunately receive much less attention,” he said.

With the new list, he said, “we want to change the focus… so that the new vaccine research and development is driven by health burden and not just commercial opportunities.”
…

geneva — World Health Organization member countries resumed negotiations Monday to finalize an agreement on pandemic prevention, with outbreaks of mpox, Marburg and H5N1 stressing the urgency of reaching an agreement without repeating the deadly mistakes of COVID-19.

After more than two years of negotiations, there is hope of reaching an agreement in the next 15 days, especially since the negotiators have agreed to postpone discussions on the most contentious points: the sharing of knowledge and equitable access to medical advances.

Recent negotiations at COP16 in Colombia on biodiversity, which provided for a comparable mechanism, stumbled on this point.

WHO chief Tedros Adhanom Ghebreyesus stressed the need to balance timeliness and workable deal.

“Time is not our friend,” Tedros told national negotiators at the opening of the talks. “COVID is still circulating. Mpox is a global health emergency. We have a Marburg outbreak and H5N1 spreading. The next pandemic will not wait.”

Never again

In December 2021, fearing a repeat of the catastrophe caused by COVID-19, which killed millions of people, the 194 member countries of WHO agreed to reach an agreement on pandemic prevention, preparedness and response.

The emergence of a new strain of mpox, the deadly Marburg virus outbreak in Rwanda and the spread of H5N1 avian flu in recent months have clarified the issues.

Diplomats have agreed on most of the draft’s 37 articles during 11 rounds of negotiations.

The main section on which consensus will need to be found concerns access to pathogens for the scientific community and medical research, and then to products to combat the pandemic such as vaccines or other tests derived from this research.

In order not to block everything, the idea is to postpone the discussion on the details of the pathogen access and benefit sharing system (PABS) until later.

Battle for fairness

For the moment, there is an impasse between rich and poor countries, which have not forgotten that they were abandoned to their fate during the COVID-19 pandemic.

“If the world has failed on one thing, it is on the issue of equity” during the COVID-19 pandemic, the head of WHO stressed on Friday.

“Africa was left behind at the time, and this should not happen,” Tedros said.

‘Bitter taste’

Helen Clark, former New Zealand Prime Minister, believes that “the South sees the North as protecting its pharmaceutical industries,” and this “has left an incredibly bitter taste between the North and the South.”

The International Federation of Pharmaceutical Manufacturers and Associations called for an agreement “allowing the private sector to innovate.”

“Intellectual property must be respected, and technology transfer must always be voluntary and on mutually agreed terms,” the federation insisted.

Among the country representatives, Malaysia, speaking on behalf of a group of developing countries known as the Equity Group, said “major improvements are still desperately needed in many areas.”

It demanded that at least 20% of real-time production of vaccines, tests and treatments go to developing countries.

Tanzania, on behalf of 48 African countries, said it could not “accept an agreement not based on equity.”

The Indonesian negotiator said an agreement that only preserves the status quo is unacceptable, because “empty promises will not save lives.”

China insisted that “quality should not be sacrificed for time.”

Germany’s representative called for an acceleration of the talks to “focus on what is achievable.”
…